Ledger.Open graph →

SEC Form D · Amendment · filed February 23, 2018

Bridge Therapeutics, Inc

Offering

—

Sold

—

Exemption

Rule 506(c)

Industry

Pharmaceuticals

Location

BIRMINGHAM, AL

Type

—

Rule 506(c): private placement that may advertise publicly; all investors must be verified accredited.

People & firms on this filing (18)

James G. Sullivan · Birmingham, ALExec · Director Kelley S. Alton · Birmingham, ALExec Joseph S. Mullin · Birmingham, ALExec · Director David H. Bergstrom · Birmingham, ALDirector Diana H. Harshbarger · Birmingham, ALDirector Elizabeth G. Kelley · Birmingham, ALDirector Stewart Kohl · Cleveland, OHExec · Director Frank H. Roessler · New York, NYDirector Joe H. Fairless · New York, NYDirector Albert Swantner · Austin, TXExec · Director Bela Szigethy · New York, NYExec Bela Schwartz · New York, NYDirector Steven B. Anderson · Buffalo, NYExec · Director Bejan Esmaili · berkeley, CADirector Anandh Hari · Waltham, MADirector Tom Naughton · Waltham, MAExec · Director Paul Ciriello · Waltham, MAExec David Stienes · Waltham, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗